Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained
How the Novo Nordisk Board Built the Weight-Loss Drug Empire
In this episode of Boardroom Conversations with Fexingo, Lucas and Luna dissect how the board of Novo Nordisk transformed a sleepy Danish insulin maker into the most valuable company in Europe, riding the Ozempic and Wegovy wave. They explore the pivotal 2014 decision to invest in semaglutide despite early clinical doubts, the board's long-term incentive structure that rewarded patience over quarterly earnings, and the governance challenge of managing explosive demand without sacrificing quality. Lucas breaks down the board's risk management framework during the supply crunch of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.